drugset / Trial / NCT01450995

Migraine Treatment Satisfaction With Treximet Versus Concomitant 2 Aleve and Imitrex

NCT01450995

Phase 4 Completed 50 enrolled Stephen H. Landy, M.D. GlaxoSmithKline · collab
RandomizedCrossoverOpen-labelTreatment

Summary

This is an open label, 6 month cross over study in 50 migraine patients fulfilling International Headache Society Classification criteria for migraine headache with and without aura having 2-6 migraines per month and not over 14 days a month of headaches in the previous 3 months. Baseline Headache Impact Test -6 (HIT-6) will be obtained and 25 patients will administer Treximet as needed for 3 months and then 2 Aleve and 100mg Imitrex taken concomitantly as needed for 3 months. The other 25 patients will administer 2 Aleve and 100mg Imitrex taken concomitantly as needed for 3 months and then Treximet as needed for 3 months. In addition to Revised Patient Perception of Migraine Questionnaire (PPMQ-R)data, a detailed diary will be recorded regarding number of tablets taken per attack, compliance, rescue treatment, when patients treated their migraine attack (mild, moderate, or severe), onset of pain reduction (pain relief and pain free, and 24 hour pain relief and sustained pain free response.

Timeline

Start
2009-12
Primary completion
2011-05
Completion
2011-05

Publications

Drugs

EvaluationDrugModalityDoseRoute
Comparator Naproxen Small molecule 440 mg
Comparator Sumatriptan Unknown 100 mg
Comparator Treximet Unknown 85 mg
Comparator Treximet Unknown 500 mg

Indications